Filtered By:
Specialty: Cancer & Oncology
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 328 results found since Jan 2013.
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
CONCLUSION: The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.PMID:37722087 | DOI:10.1200/JCO.23.00493
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Rifaquat Rahman Lorenzo Trippa Eudocia Q Lee Isabel Arrillaga-Romany Geoffrey Fell Mehdi Touat Christine McCluskey Jennifer Wiley Sarah Gaffey Jan Drappatz Mary R Welch Evanthia Galanis Manmeet S Ahluwalia Howard Colman L Burt Nabors Jaroslaw Hepel Heinri Source Type: research
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide
Acta Oncol. 2023 Sep 15:1-4. doi: 10.1080/0284186X.2023.2258444. Online ahead of print.NO ABSTRACTPMID:37713358 | DOI:10.1080/0284186X.2023.2258444
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Annika Marie Ørting Malene Martini Clausen Patrick Soldath Rene H Petersen Ulrich Knigge Mikkel Andreassen Andreas Kj ær Seppo W Langer Source Type: research
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
CONCLUSIONS AND RELEVANCE: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.PMID:37676712 | DOI:10.1093/oncolo/oyad257
Source: The Oncologist - September 7, 2023 Category: Cancer & Oncology Authors: Çağlar Ünal Abdulmunir Azizy Senem Karabulut Didem Ta ştekin Arif Aky ıldız Serkan Ya şar Şuayib Yalçın Ey üp Çoban T ürkkan Evrensel Ziya Kalkan Zeynep Oru ç S ümeyra Derin Zeynep Hande Turna Do ğan Bayram Fahriye Tu ğba Köş Mehmet Ali Source Type: research
Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
In conclusion, we demonstrate targeted RNA-guided methylation of the MGMT promoter as a promising tool to overcome chemoresistance and improve the cytotoxic effect of TMZ in glioblastoma.PMID:37634280 | DOI:10.1016/j.neo.2023.100929
Source: Neoplasia - August 27, 2023 Category: Cancer & Oncology Authors: Xinyu Han Mohammed O E Abdallah Peter Breuer Fabian Stahl Yousuf Bakhit Anna-Laura Potthoff Barbara E F Pregler Matthias Schneider Andreas Waha Ullrich W üllner Bernd O Evert Source Type: research
EZH2-regulated PARP 1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide
CONCLUSION: EZH2 PARP 1 signaling axis is possibly responsible for the chemoresistance of gliomas to TMZ. Simultaneously inhibiting these two genes may improve the outcome of TMZ chemotherapy.PMID:37594167 | DOI:10.2174/1568009623666230818151830
Source: Current Cancer Drug Targets - August 18, 2023 Category: Cancer & Oncology Authors: Qiang Liang Bing Wang Chenran Zhang Chaoli Song Junyu Wang Wei Sun Lei Jiang Jing Lin Source Type: research
